Previously he served as Vice President of Corporate Development and Investor Relations at Javelin Pharmaceuticals, a publicly traded company that developed Dyloject through EMEA approval, launch ...

With FDA approval now in hand, Dyloject, an injectable nonsteroidal anti-inflammatory drug, could fill the void left by the expiration of most of the patents protecting Hospira's sedative ...

Dyloject's approval is based on two double-blind, placebo and active-controlled, multiple-dose clinical trials of adult patients with postoperative pain. In both trials, ...

The FDA has approved Hospira, Inc.’s (HSP) proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic, Dyloject. The drug is approved for use in adults for the management of mild-to ...

Non-opioid analgesic injectable Dyloject has received FDA approval, adding to the list of NSAID options available to patients for safe, effective and non-addicting pain relief.

US injectable drugs and infusion technologies specialist Hospira (NYSE: HSP) has received approval from the US Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary ...

New nonsteroidal anti-inflammatory drug (NSAID) medication used for management of mild to severe pain in adults. LAKE FOREST, IL, USA I December 30, 2014 I Hospira, Inc. (NYSE: HSP), the world’s ...

Hospira Inc said the U.S. Food and Drug Administration had approved its non-opioid injection that provides faster relief to patients suffering moderate to severe pain.

Hospira Inc said on Tuesday the U.S. Food and Drug Administration approved its injectable drug to manage moderate to severe pain. The drug, Dyloject, can be used alone, or in combination with non ...

Dyloject will be available as a 37.5mg/mL strength vials in 25-count cartons. For more information call (800) 441-4100 or visit Hospira.com.